Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse

European Neurology

Volumn 52, Issue 4, 2004, Pages 237-241

  Bartosik Psujek, Halina ^a   Stelmasiak, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

CCL2 chemokine; CCL5 chemokine; Multiple sclerosis; Relapsing remitting multiple sclerosis; Steroid therapy

Indexed keywords

METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 5; STEROID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; STEROID THERAPY;

ADULT; ANTI-INFLAMMATORY AGENTS; CHEMOKINE CCL2; CHEMOKINES, CC; DESONIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; STATISTICS, NONPARAMETRIC;

EID: 12544249257     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082164     Document Type: Article

References (25)

1. Moser B, Loetscher P: Lymphocyte traffic control by chemokines. Nat Immunol 2001;2:123-128.
2. Luster A: Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-445.
3. Sellebjerg F, Sørensen TL: Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull 2003;61:347-355.
4. Zlotnik A, Yoshie O: Chemokines: A new classification system and their role in immunity. Immunity 2000;12:121-127.
5. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM: Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-815.
6. Iarlori C, Reale M, Lugaresi A, De Luca G, Bonanni L, Di Iorio A, Feliciani C, Conti P, Gambi D: RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon β-1b. J Neuroimmunol 2000;107:100-107.
7. Sindern E, Niederkinkhaus Y, Henschel M, Ossege LM, Patzold T, Malin JP: Differential release of beta-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 2001;104:88-91.
8. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V: Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001;115:192-198.
9. Sørensen TL, Sellebjerg F, Jensen J, Strieter RM, Ransohoff R: Chemokines CXCL10 and CCL2: Differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol 2001;8:665-672.
10. Mahad DJ, Howell SJ, Woodroofe MN: Expression of chemokines in the CSF and correlation with clinical disease actvity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;72:498-502.
11. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN: Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998;84:238-249.
12. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS: Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
13. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
14. Li QQ, Bever CT: Th1 cytokines stimulate RANTES chemokine secretion by human astroglial cells depending on de novo transcription. Neurochem Res 2001;26:125-133.
15. Glabinski AR, Bielecki B, Ransohoff RM: Chemokine upregulation follows cytokine expression in chronic relapsing experimental autoimmune encephalomyelitis. Scand J Immunol 2003;58:81-88.
16. Bar-Or A, Oliveira EM, Anderson DE, Hafler DA: Molecular pathogenesis of multiple sclerosis. J Neuroimmunol 1999;100:252-259.
17. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins B: Control of Th2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000;404:407-411.
18. Lewis AJ, Manning AM: New targets for antiinflammatory drugs. Curr Opin Chem Biol 1999,3:489-494.
19. Barnes PJ, Karin M: Nuclear factor-kappa B: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
20. Moriuchi H, Moriuchi M, Fauci AS: Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol 1997;158:3483-3491.
21. DeKruyff RH, Fang Y, Umetsu DT: Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J Immunol 1998;160:2231-2237.
22. Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, Frucht DM, Chrousos GP, O'Shea JJ: Inhibition of Th1 immune response by glucocorticoids: Dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol 2000;164:1768-1774.
23. So EY, Kim SH, Park HH, Cho BS, Lee CE: Corticosteroid inhibits IL-4 signaling through down-regulation of IL-4 receptor and STAT6 activity. FEBS Lett 2002;518:53-59.
24. Franciotta D, Zardini E, Bergamaschi R, Andreoni L, Cosi V: Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment. J Neurol Neurosurg Psychiatry 2003;74:123-126.
25. Buttgereit F, Scheffold A: Rapid glucocorticoid effects on immune cells. Steroids 2002;67:529-534.